Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

“Third, Biogen’s been running on fumes while it works on its Alzheimer’s drug, but the fumes, basically a very good MS drug, in a crowded field, aren’t enough. Not with the unmet projectio ...

Biogen’s top-line remains heavily reliant on its multiple sclerosis (MS) portfolio, which accounts for over 60% of 2024 revenue, including royalties from Ocrevus. Piper Sandler flagged several ...

There has also been a shift in treatment preferences over the years in MS towards B-cell depleting therapies like Roche's (OTCQX:RHHBY) Ocrevus (Biogen earned $346.8 million in Q3 from Ocrvus ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

That’s the message Biogen chief executive Chris Viehbacher conveyed to Governor Maura Healey, during a Q&A session following her speech on Thursday at an Associated Industries of Massachusetts ...

Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...

Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Exchange Traded Concepts LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.5% during the 4th ...